Although it has now been well established that KRAS mutation is a negative predictor for response to anti-EGFR therapy (Allegra et al, 2009; Balko and Black, 2009; Baynes and Gansert, 2009; Javle and Hsueh, 2009; Jimeno et al, 2009; Kohne and Lenz, 2009; Loupakis et al, 2009; Peeters et al, 2009; Saif and Shah, 2009), the prognostic role of KRAS mutations in CRC is still unclear (as reviewed by Anwar et al, 2004; Klump et al, 2004; Locker et al, 2006). Here, EGFR is linked to colorectal carcinoma.